Angel L. Pey
Granada, AN 18071, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 82 publications
Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1.
Journal: Journal of medicinal chemistry
Published: January 02, 2026
Minimized sample consumption for time-resolved serial crystallography applied to the redox cycle of human NQO1.
Journal: Communications chemistry
Published: November 11, 2025
Tyrosine residues at the substrate binding site in human NQO1 homodimer: Protein conformational dynamics and optimization of substrate binding geometry.
Journal: The FEBS journal
Published: October 20, 2025
Nanobodies as therapies for loss-of-function misfolding diseases: the example of Primary Hyperoxaluria Type 1.
Journal: International journal of biological macromolecules
Published: May 09, 2025
The lack of trade-off between conformational stability and binding affinity in a nanobody with therapeutic potential for a misfolding disease.
Journal: International journal of biological macromolecules
Published: September 22, 2024
Structural dynamics and functional cooperativity of human NQO1 by ambient temperature serial crystallography and simulations.
Journal: Protein science : a publication of the Protein Society
Published: December 21, 2023
Phosphorylation of cytosolic hPGK1 affects protein stability and ligand binding: implications for its subcellular targeting in cancer.
Journal: The FEBS journal
Published: October 27, 2023
Insights into the pathogenesis of primary hyperoxaluria type I from the structural dynamics of alanine:glyoxylate aminotransferase variants.
Journal: FEBS letters
Published: October 13, 2023
Modular droplet injector for sample conservation providing new structural insight for the conformational heterogeneity in the disease-associated NQO1 enzyme.
Journal: Lab on a chip
Published: June 09, 2023
Last Updated: 09/26/2026